organization · Reporting owner
Johnson & Johnson Innovation - JJDC, Inc.
Disclosed activity across 18 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | 10% owner | May 01, 2014 | May 05, 2014 |
| BARRIER THERAPEUTICS INCBTRX · Entity 13927 | 10% owner | February 15, 2005 | February 15, 2005 |
| CRITICAL THERAPEUTICS INCCRTX · Entity 14044 | 10% owner | June 02, 2004 | June 02, 2004 |
| Contineum Therapeutics, Inc.CTNM · Entity 5311 | 10% owner | April 09, 2024 | April 10, 2024 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | 10% owner | August 16, 2016 | August 18, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date May 01, 2014 · Filed May 05, 2014
Jointly reported with JOHNSON & JOHNSON
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Development Corporation | 1,750,292 |
Last balance in matching sequence
After 2014-05-01 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2014-05-01 · Conversion · Acquired 1,724,478 · Balance 1,724,478 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2014-05-01 · Exercise / conversion · Acquired 36,345 · Balance 1,760,823 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 3 · 2014-05-01 · Tax withholding · Disposed 23,438 · Balance 1,737,385 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 4 · 2014-05-01 · Exercise / conversion · Acquired 36,345 · Balance 1,773,730 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 5 · 2014-05-01 · Tax withholding · Disposed 23,438 · Balance 1,750,292 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2014-05-01 · Conversion · Disposed 385,800 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Non-Voting Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2014-05-01 · Conversion · Disposed 104,396 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2014-05-01 · Conversion · Disposed 427,591 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Non-Voting Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2014-05-01 · Conversion · Disposed 133,827 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2017-12-20 | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2014-05-01 · Exercise / conversion · Disposed 36,345 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.16 · Expires 2018-08-14 | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-05-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2014-05-01 · Exercise / conversion · Disposed 36,345 · Balance 0 F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2: All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock converted into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis.
F3: All outstanding warrants were net exercised for shares of the Issuer's Series B Preferred Stock and subsequently automatically converted into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis.
BARRIER THERAPEUTICS INC
Report date February 15, 2005 · Filed February 15, 2005
Jointly reported with JOHNSON & JOHNSON, Johnson & Johnson Consumer Companies, Inc., Janssen Pharmaceutica Products, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy three subsidiaries | 3,753,749 |
Reported balance
After 2005-02-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2005-02-15 · Sale · Disposed 694,327 · Balance 3,753,749 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person: Johnson & Johnson Development Corporation ("JJDC") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. ("JJCC") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. ("JPP") (selling 508,689 shares of Common Stock). Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following wholly-owned subsidiaries of the Reporting Person: Johnson & Johnson Development Corporation ("JJDC") (selling 25,000 shares of Common Stock); Johnson & Johnson Consumer Companies, Inc. ("JJCC") (selling 160,638 shares of Common Stock); and Janssen Pharmaceutica Products, L.P. ("JPP") (selling 508,689 shares of Common Stock). Following the reported sale, JJDC will own 256,410 shares of Common Stock; JJCC will own 856,028 shares of Common Stock; and JPP will own 2,641,311 shares of Common Stock.
CRITICAL THERAPEUTICS INC
Report date June 02, 2004 · Filed June 02, 2004
Jointly reported with JOHNSON & JOHNSON
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Development Corporation | 2,104,704 |
Last balance in matching sequence
After 2004-06-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2004-06-02 · Conversion · Acquired 1,961,904 · Balance 1,961,904 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. Row 2 · 2004-06-02 · Purchase · Acquired 142,800 · Balance 2,104,704 F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2004-06-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2004-06-02 · Conversion · Disposed 2,000,000 · Balance 0 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2004-06-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2004-06-02 · Conversion · Disposed 5,357,143 · Balance 0 F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering.
F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person.
Contineum Therapeutics, Inc.
Report date April 09, 2024 · Filed April 10, 2024
Jointly reported with JOHNSON & JOHNSON
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,979,173 |
Reported balance
Holding disclosure · report date 2024-04-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,979,173 F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.
Protagonist Therapeutics, Inc
Report date August 16, 2016 · Filed August 18, 2016
Jointly reported with JOHNSON & JOHNSON
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 2,449,183 |
Last balance in matching sequence
After 2016-08-16 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2016-08-16 · Conversion · Acquired 965,517 · Balance 965,517 F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2016-08-16 · Conversion · Acquired 900,333 · Balance 1,865,850 F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 3 · 2016-08-16 · Purchase · Acquired 583,333 · Balance 2,449,183 F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2016-08-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-08-16 · Conversion · Disposed 14,000,000 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2016-08-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-08-16 · Conversion · Disposed 13,054,830 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date. F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration. F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date.
F2: The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration.
F3: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
Past disclosures · reporting ended (13)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date November 20, 2017 · Filed November 22, 2017
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2017-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2017-11-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-11-20 · Sale · Disposed 18,367,346 · Balance 0 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
CVRx, Inc.
Report date November 25, 2025 · Filed January 08, 2026 · Amendment
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2024-02-02. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 4,024,861 |
Last balance in matching sequence
After 2025-11-26 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-11-25 · Sale · Disposed 16,000 · Balance 4,031,198 F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. Row 2 · 2025-11-26 · Sale · Disposed 6,337 · Balance 4,024,861 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.23. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Fusion Pharmaceuticals Inc.
Report date June 30, 2020 · Filed July 02, 2020
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 3,670,516 |
Last balance in matching sequence
After 2020-06-30 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2020-06-30 · Conversion · Acquired 2,945,516 · Balance 2,945,516 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2020-06-30 · Purchase · Acquired 725,000 · Balance 3,670,516 F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Class A Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2020-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-30 · Conversion · Disposed 10,666,667 · Balance 0 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Class B Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2020-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-30 · Conversion · Disposed 5,059,460 · Balance 0 F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Warrants to purchase Class B Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2020-06-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-30 · Conversion · Disposed 475,802 · Balance 0 F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Warrants to purchase Common SharesSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 89,118 |
Reported balance
After 2020-06-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-06-30 · Conversion · Acquired 89,118 · Balance 89,118 F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class A Preferred Shares and Class B Preferred Shares automatically converted into Common Shares on a one-for-5.339 basis upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Shares had no expiration date.
F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
F3: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares converted to Warrants to purchase Common Shares at an exercise price of $8.10 per share.
GENOCEA BIOSCIENCES, INC.
Report date February 10, 2014 · Filed February 11, 2014
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2014-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Development Corporation | 1,388,645 |
Reported balance
After 2014-02-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2014-02-10 · Conversion · Acquired 1,388,645 · Balance 1,388,645 F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2014-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2014-02-10 · Conversion · Disposed 827,917 · Balance 0 F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | Not disclosed |
Reported balance
After 2014-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2014-02-10 · Conversion · Disposed 351,866 · Balance Not disclosed F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2: Upon closing of the Issuer's initial public offering (the "IPO") the Series B Preferred Stock, including all accrued and unpaid dividends, converted automatically into Common Stock on a 1-for-11.9 basis without payment of further consideration. The Series B Preferred Stock had an accruing cumulative dividend that accrued at a rate of 8% per year from the Series B Preferred Stock issuance date. 208,862 shares were issued to Johnson & Johnson Development Corporation in payment of accrued and unpaid dividends. Upon closing of the IPO the Series C Preferred Stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration. There was no expiration date for any series of preferred stock.
IMMUNICON CORP
Report date June 10, 2004 · Filed June 14, 2004
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2004-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Development Corporation | 1,771,571 |
Reported balance
After 2004-06-10 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2004-06-10 · Other · Acquired 2,667 · Balance 1,771,571 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. |
| Common Stock Warrant PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2004-07-14 | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2004-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2004-06-10 · Other · Disposed 2,667 · Balance 0 F2: Pursuant to the terms of the warrant, the Reporting Persons had 90 days from the date JJDC's director designee resigned from the Issuer's Board of Directors to exercise the warrant as no other director designee was selected by JJDC. JJDC's director designee resigned from the board on April 15, 2004, triggering the 90 day period. F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person.
F2: Pursuant to the terms of the warrant, the Reporting Persons had 90 days from the date JJDC's director designee resigned from the Issuer's Board of Directors to exercise the warrant as no other director designee was selected by JJDC. JJDC's director designee resigned from the board on April 15, 2004, triggering the 90 day period.
Inspire Medical Systems, Inc.
Report date May 07, 2018 · Filed May 07, 2018
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2018-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 235,251 |
Last balance in matching sequence
After 2018-05-07 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-05-07 · Conversion · Acquired 197,863 · Balance 197,863 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2018-05-07 · Conversion · Acquired 37,388 · Balance 235,251 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series E Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2018-05-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-07 · Conversion · Disposed 1,145,038 · Balance 0 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series F Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2018-05-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-07 · Conversion · Disposed 248,631 · Balance 0 F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering. F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate. F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Series E and Series F Convertible Preferred Stock have no expiration date and were automatically converted into shares of Common Stock for no additional consideration immediately prior to the closing of the Issuer's initial public offering.
F2: Shares of Series E Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1728 conversion rate.
F3: Shares of Series F Convertible Preferred Stock converted into shares of Common Stock at a 1-for-0.1504 conversion rate.
F4: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
MeiraGTx Holdings plc
Report date September 15, 2023 · Filed September 18, 2023
Section 16 reporting ended · disclosed 2023-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,641,064 |
Reported balance
Holding disclosure · report date 2023-09-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,641,064 F1: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 4 will be filed to disclose Old JJDC's disposition of the securities reported herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law, ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 4 will be filed to disclose Old JJDC's disposition of the securities reported herein.
Minerva Neurosciences, Inc.
Report date August 29, 2017 · Filed September 14, 2017
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2017-09-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2017-08-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-08-29 · Other · Disposed 3,892,256 · Balance 0 F1: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc. F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were repurchased by the Issuer at their par value in connection with the amendment of a co-development and license agreement between the Issuer and an affiliate of Johnson & Johnson Innovation - JJDC, Inc.
F2: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the Reporting Person.
NEVRO CORP
Report date December 31, 2015 · Filed February 12, 2016
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2016-02-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 2,066,740 |
Reported balance
After 2015-06-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2015-06-08 · Sale · Disposed 1,010,265 · Balance 2,066,740 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owed subsidiary of the Reporting Person.
Neurogene Inc.
Report date August 10, 2015 · Filed August 12, 2015
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2015-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Innovation - JJDC, Inc. | 100,000 |
Last balance in matching sequence
After 2015-08-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2015-08-10 · Sale · Disposed 231,455 · Balance 1,383,366 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014. Row 2 · 2015-08-11 · Sale · Disposed 1,283,366 · Balance 100,000 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $30.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. Johnson & Johnson Development Corporation changed its name to Johnson & Johnson Innovation - JJDC, Inc. on November 3, 2014.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $41.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $30.00. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Provention Bio, Inc.
Report date July 19, 2018 · Filed July 20, 2018
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2018-07-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 2,400,000 |
Reported balance
After 2018-07-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-07-19 · Conversion · Acquired 2,400,000 · Balance 2,400,000 F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Innovation - JJDC, Inc. | 0 |
Reported balance
After 2018-07-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-19 · Conversion · Disposed 2,400,000 · Balance 0 F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering. F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Preferred Stock had no expiration date and was automatically converted into shares of Common Stock on a 1-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering.
F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
TENGION INC
Report date April 14, 2010 · Filed April 14, 2010
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2010-04-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJohnson & Johnson Development Corporation | 1,194,654 |
Last balance in matching sequence
After 2010-04-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2010-04-14 · Conversion · Acquired 755,053 · Balance 794,654 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. Row 2 · 2010-04-14 · Purchase · Acquired 400,000 · Balance 1,194,654 F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2010-04-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2010-04-14 · Conversion · Disposed 4,961,653 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2010-04-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2010-04-14 · Conversion · Disposed 2,162,818 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Johnson & Johnson Development Corporation | 0 |
Reported balance
After 2010-04-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2010-04-14 · Conversion · Disposed 3,823,817 · Balance 0 F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration. F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
F2: There is no expiration date applicable to the Series A, Series B or Series C Preferred Stock. Subject to certain conditions, immediately prior to the closing of the Issuer's initial public offering each share of Series A, Series B and Series C Preferred Stock automatically converted into shares of Common Stock on a 14.5-for-1 basis, for no additional consideration.
UNIVERSAL BIOSENSORS INC
Report date December 31, 2011 · Filed January 24, 2012
Jointly reported with JOHNSON & JOHNSON
Section 16 reporting ended · disclosed 2012-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Johnson & Johnson Development Corporation | 15,749,937 |
Last balance in matching sequence
After 2011-09-08 transaction · row 17
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
17 source rowsRow 1 · 2011-03-08 · Sale · Disposed 25,000 · Balance 17,406,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 2 · 2011-03-09 · Sale · Disposed 25,000 · Balance 17,381,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 3 · 2011-03-10 · Sale · Disposed 25,000 · Balance 17,356,617 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 4 · 2011-03-21 · Sale · Disposed 4,900 · Balance 17,351,717 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 5 · 2011-03-29 · Sale · Disposed 32 · Balance 17,351,685 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 6 · 2011-03-30 · Sale · Disposed 155 · Balance 17,351,530 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 7 · 2011-04-14 · Sale · Disposed 10,000 · Balance 17,341,530 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 8 · 2011-04-15 · Sale · Disposed 7,500 · Balance 17,334,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 9 · 2011-04-18 · Sale · Disposed 8,000 · Balance 17,326,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 10 · 2011-04-20 · Sale · Disposed 10,000 · Balance 17,316,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 11 · 2011-04-21 · Sale · Disposed 35,000 · Balance 17,281,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 12 · 2011-04-27 · Sale · Disposed 10,000 · Balance 17,271,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 13 · 2011-04-28 · Sale · Disposed 10,000 · Balance 17,261,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 14 · 2011-04-29 · Sale · Disposed 10,000 · Balance 17,251,030 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 15 · 2011-07-28 · Sale · Disposed 341 · Balance 17,250,689 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 16 · 2011-08-01 · Sale · Disposed 752 · Balance 17,249,937 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. Row 17 · 2011-09-08 · Sale · Disposed 1,500,000 · Balance 15,749,937 F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owed subsidiary of the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2004 Filed Jun 2, 2004 19:24 UTC | CRITICAL THERAPEUTICS INC CRTX · Entity 14044 | PurchaseCommon Stock | 142,800 | $7.00 | $999,600.00 |
DisclosureSEC source: 0000904454-04-000380 · edgar.xml · nonDerivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 2,104,704 F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. Read SEC document |
| June 02, 2004 Filed Jun 2, 2004 19:24 UTC | CRITICAL THERAPEUTICS INC CRTX · Entity 14044 | ConversionCommon Stock | 1,961,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-04-000380 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 1,961,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the preferred stock was automatically converted on a 1-for-3.75 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. Read SEC document |
| June 02, 2004 Filed Jun 2, 2004 19:32 UTC | IMMUNICON CORP IMMC · Entity 14039 | OtherCommon Stock Purchase Warrant · Derivative | 2,667 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000904454-04-000382 · edgar.xml · derivative · entry 4 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 2,667 shares Expires 2004-07-14 F2 · derivative.exercise_date: The warrant was 50% vested (as to 2,667 shares) as of 1/16/04. The remaining 2,667 shares will never become exercisable, and will be surrendered to the Issuer, because JJDC's director designee resigned from the Issuer's Board of Directors. F2 · balance_after: The warrant was 50% vested (as to 2,667 shares) as of 1/16/04. The remaining 2,667 shares will never become exercisable, and will be surrendered to the Issuer, because JJDC's director designee resigned from the Issuer's Board of Directors. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. Read SEC document |
| June 02, 2004 Filed Jun 2, 2004 19:32 UTC | IMMUNICON CORP IMMC · Entity 14039 | OtherCommon Stock Purchase Warrant · Derivative | 5,334 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000904454-04-000382 · edgar.xml · derivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 5,334 shares Expires 2004-07-14 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. Read SEC document |
| June 02, 2004 Filed Jun 2, 2004 19:32 UTC | IMMUNICON CORP IMMC · Entity 14039 | OtherCommon Stock Warrant Purchase · Derivative | 2,667 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0000904454-04-000382 · edgar.xml · derivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 2,667 shares Expires 2004-07-14 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. Read SEC document |
| June 02, 2004 Filed Jun 2, 2004 19:32 UTC | IMMUNICON CORP IMMC · Entity 14039 | OtherCommon Stock | 10,668 | $2.40 | $25,603.20 |
DisclosureSEC source: 0000904454-04-000382 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 15,668 F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation ("JJDC"), a wholly-owned subsidiary of the Reporting Person. Read SEC document |
| April 28, 2004 Filed Jun 4, 2004 14:16 UTC Amendment | BARRIER THERAPEUTICS INC BTRX · Entity 13927 | ConversionSeries C Convertible Preferred Stock · Derivative | 512,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-04-000085 · edgar.xml · derivative · entry 4 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Janssen Pharmaceutica Products, L.P. · CIK 0001290895 · 10% owner Johnson & Johnson Consumer Companies, Inc. · CIK 0001290934 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F6 · price: Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F6 · derivative.exercise_date: Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F6 · derivative.expiration_date: Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F6 · derivative.underlying_shares: Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F7 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person: Johnson & Johnson Development Corporation. F8 · ownership.nature: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers. Read SEC document |
| April 28, 2004 Filed Jun 4, 2004 14:16 UTC Amendment | BARRIER THERAPEUTICS INC BTRX · Entity 13927 | ConversionSeries B Convertible Preferred Stock · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-04-000085 · edgar.xml · derivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Janssen Pharmaceutica Products, L.P. · CIK 0001290895 · 10% owner Johnson & Johnson Consumer Companies, Inc. · CIK 0001290934 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F4 · price: Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F4 · derivative.exercise_date: Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F4 · derivative.expiration_date: Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F4 · derivative.underlying_shares: Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F5 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person: Johnson & Johnson Development Corporation. F8 · ownership.nature: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers. Read SEC document |
| April 28, 2004 Filed Jun 4, 2004 14:16 UTC Amendment | BARRIER THERAPEUTICS INC BTRX · Entity 13927 | ConversionSeries A Convertible Preferred Stock · Derivative | 8,333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000200406-04-000085 · edgar.xml · derivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Janssen Pharmaceutica Products, L.P. · CIK 0001290895 · 10% owner Johnson & Johnson Consumer Companies, Inc. · CIK 0001290934 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F2 · price: Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F2 · derivative.exercise_date: Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F2 · derivative.expiration_date: Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F2 · derivative.underlying_shares: Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering. F3 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person: Johnson & Johnson Consumer Companies, Inc.; Janssen Pharmaceutica Products, L.P. F8 · ownership.nature: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers. Read SEC document |
| April 28, 2004 Filed Jun 4, 2004 14:16 UTC Amendment | BARRIER THERAPEUTICS INC BTRX · Entity 13927 | ConversionCommon Stock | 4,448,076 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-04-000085 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner Janssen Pharmaceutica Products, L.P. · CIK 0001290895 · 10% owner Johnson & Johnson Consumer Companies, Inc. · CIK 0001290934 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,448,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person: Johnson & Johnson Consumer Companies, Inc. (1,016,666 shares of Common Stock); Janssen Pharmaceutica Products, L.P. (3,150,000 shares Common Stock); Johnson & Johnson Development Corporation (281,410 shares Common Stock). F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person: Johnson & Johnson Consumer Companies, Inc. (1,016,666 shares of Common Stock); Janssen Pharmaceutica Products, L.P. (3,150,000 shares Common Stock); Johnson & Johnson Development Corporation (281,410 shares Common Stock). F8 · ownership.nature: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation, Janssen Pharmaceutica Products, L.P. and Johnson & Johnson Consumer Companies, Inc. as joint filers. Read SEC document |
| April 21, 2004 Filed May 28, 2004 18:56 UTC Amendment | IMMUNICON CORP IMMC · Entity 14039 | ConversionSeries F Preferred Stock · Derivative | 1,575,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-04-000374 · edgar.xml · derivative · entry 3 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 1,050,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: All of the outstanding shares of the Issuer's Series F Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3 · price: All of the outstanding shares of the Issuer's Series F Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: All of the outstanding shares of the Issuer's Series F Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: All of the outstanding shares of the Issuer's Series F Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. F4 · ownership.nature: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation as a joint filer. Read SEC document |
| April 21, 2004 Filed May 28, 2004 18:56 UTC Amendment | IMMUNICON CORP IMMC · Entity 14039 | ConversionSeries E Preferred Stock · Derivative | 1,054,853 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-04-000374 · edgar.xml · derivative · entry 2 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 0 Underlying: Common Stock · 703,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All of the outstanding shares of the Issuer's Series E Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2 · price: All of the outstanding shares of the Issuer's Series E Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: All of the outstanding shares of the Issuer's Series E Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F2 · derivative.expiration_date: All of the outstanding shares of the Issuer's Series E Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. F4 · ownership.nature: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation as a joint filer. Read SEC document |
| April 21, 2004 Filed May 28, 2004 18:56 UTC Amendment | IMMUNICON CORP IMMC · Entity 14039 | ConversionCommon Stock | 1,753,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000904454-04-000374 · edgar.xml · nonDerivative · entry 1 JOHNSON & JOHNSON · CIK 0000200406 · 10% owner JOHNSON & JOHNSON DEVELOPMENT CORP ET AL · CIK 0000924020 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Johnson & Johnson Development Corporation Disclosed balance after: 1,758,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: All of the outstanding shares of the Issuer's Series E Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F3 · price: All of the outstanding shares of the Issuer's Series F Convertible Preferred Stock were automatically converted on a 1-for-1.5 basis into Common Stock of the Issuer upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the Reporting Person. F4 · ownership.nature: The reported transactions are not new or revised but are being reported again to gain access to the system to file this amendment, the sole purpose of which is to add Johnson & Johnson Development Corporation as a joint filer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.